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Background: The evidence on determinants of individuals’ choices for anti-malarial drug treatments is scarce. This
study sought to measure the strength of preference for adult antimalarial drug treatment attributes of heads of
urban, rural and peri-urban households in a resource-limited malaria-endemic area of sub-Saharan Africa.
Methods: Discrete choice experiments were conducted with 508 heads of household interviewed face-to-face
for a household population survey of health-seeking behavior in Zomba District, Malawi. The interviews were
held in Chichewa and the choice experiment questions were presented with cartoon aids. The anti-malarial
drug attributes included in the stated preference experiment were: speed of fever resolution, side effects (pruritus)
risk, protection (duration of prophylactic effect), price, duration of treatment course and recommendation by a health
professional. Sixteen treatment profiles from a fractional factorial design by orthogonal array were paired into choice
scenarios, and scenarios were randomly assigned to participants so that each participant was presented with a series
of eight pairwise choice scenarios. Respondents had the option to state indifference between the two profiles
or decline to choose. Data were analysed in a mixed logit model, with normally distributed coefficients for all
six attributes.
Results: The sex ratio was balanced in urban areas, whereas 63% of participants in rural areas were male. The
proportion of individuals with no education was considerably higher in the rural group (25%) than in the urban (5%)
and peri-urban (6%) groups. All attributes investigated had the expected influence, and traded-off in most respondents’
choices. There were heterogeneous effects of price, pruritus risk, treatment recommendation by a professional, and
duration of prophylaxis across respondents, only partly explained by their differences in education, household per
capita expenditure, sex and age. Individuals´ demand elasticity (simulated median, inter-quartile range) was highest
(most responsive) to speed of symptom resolution (0.88, 0.80-0.89) and pruritus risk (0.25, 0.08-0.62).
Conclusions: Most adult antimalarial users are willing to use treatments without recommendation from health
professional, and may be influenced by price. Future studies should investigate the magnitude of differences in
price and treatment attribute sensitivity between adult anti-malarial drug users in rural, peri-urban and urban areas
in order to determine optimal price subsidies.
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In sub-Saharan Africa, anti-malarial drug treatment may
be accessed through the informal and formal sectors.
Self-medication through purchases from kiosks or phar-
macies is common, providing over the counter access to
a range of treatments, including drugs that are not part
of the government’s national anti-malarial programme
and prescription-only drugs reserved for second-line
treatment [1,2]. Despite the fact that there is growing
evidence about treatment-seeking behaviour patterns
and strategies used by households to cope with symp-
toms resembling malaria in endemic countries [3-11],
there is limited evidence on the factors that determine
the choices made by individuals who purchase anti-
malarial medication from shops and pharmacies.
In western Uganda, a study examined the acceptability
of drug presentation characteristics by asking women
aged 15–49 to state a preference for pre-packed or con-
ventional, loose tablet dispensing of anti-malarial drugs
for children at government health facilities, including
the reasons for their preference, their willingness to pay
for pre-packaging, and their actions in the hypothetical
event that the pre-packed dose for the required child age
was not available [12]. However, no study appears to have
considered the role of the attributes of the anti-malarial
drugs themselves on treatment choice. Identification of
factors that are seen as desirable by consumers of anti-
malarials would help to inform the design of interven-
tions to improve the management of cases presenting
with malaria-like symptoms in the community and
would also allow policy-makers to design more effective
strategies for the implementation of anti-malarial treat-
ment policy in the region. Such information is particu-
larly important at a time when artemisinin combination
therapy (ACT) is now used as first-line therapy through-
out much of Africa and is increasingly available in the
informal sector across Africa.
Stated preference methods provide a rigorous, system-
atic framework for inferring such factors, by examining
responses to hypothetical choices between two or more
prototype drugs defined in terms of a set of charac-
teristics believed to represent attributes relevant to
real individual purchasing decisions. Since hypothetical
drug options presented to any given individual are gener-
ated randomly from the range of possible values that each
and every attribute may take, associations of drug choices
and characteristics may be given a causal interpretation.
Moreover, by seeking to replicate a real life decision situ-
ation, this technique provides an alternative approach to
explicitly eliciting answers from respondents about desir-
able attributes and their importance. In health, stated
preference methods, sometimes misleadingly referred to
as conjoint analyses, have been used to explore issues
ranging from the evaluation of prescription decisions[13], the introduction of chicken pox vaccination [14], to
patient preferences for managing asthma [15].
This study aims to identify individuals’ strength of
preference for combinations of anti-malarial drug attri-
butes in the Zomba District of Malawi. Attributes inves-
tigated relate to the clinical effects of the drug, cost of
acquiring the drug in the market, the duration of treat-
ment and the status of the drug in the prescribing rec-
ommendations of health professionals. This study does
not consider issues of access or preferred source of drug,
which although pertinent to choice in real life, need to
be studied separately.
Methods
The factors chosen to be evaluated in our stated prefer-
ence study were identified by a prior qualitative study
conducted in three sites in rural and peri-urban areas in
Zomba. Focus group discussions (FGDs) were held with
adults to elicit their views on the most important anti-
malarial drug characteristics and their ranking. A total of
13 FGDs, each with 5–10 participants, were conducted; six
FGDs included only men, six were held exclusively with
women and one had a mixed gender composition for veri-
fying and validating emerging issues and themes. The total
number of FGDs was determined by the attainment of
saturation (i.e., when new groups stopped adding new
information to the discussion).
The qualitative study identified and ranked the follow-
ing as the most important attributes of anti-malarial
drugs: speed of fever resolution, side effects, protection
(prophylaxis) and price. Duration of treatment course
and recommendation by a health professional were also
included, since they were implicitly referred to as being
important by respondents in the qualitative study.
Once the attributes were identified, each of the charac-
teristics was assigned realistic levels i.e., time to fever
resolution, 24 hrs. vs. 12 hrs.; side effects defined as the risk
of rash (pruritus), 1 vs. 3 in 10 individuals; protection from
re-infection (prophylactic effect), 10 days vs. 50 days; price
paid, 500 Kwachas (US$4.62, high; $1 = Malawian
Kwacha108.84), 200 Kwachas (US$1.85, medium), and 50
Kwachas (US$0.46, low); duration of treatment course, 1
vs. 3 days; and whether recommended by a health profes-
sional (yes or no). These values were intended to encom-
pass the characteristics of sulfadoxine-pyrimethamine (SP)
and ACT, respectively, the former and new official first-line
treatments in Malawi. The terms ‘price’ and ‘cost’ are used
interchangeably in what follows (since the price of antima-
larials obtained from shops and pharmacies is paid by the
user), to facilitate continuity in exposition between statis-
tical models, which differ in how the price attribute is
included in the model (see Data analysis).
The specification of experimental profiles was a frac-
tional factorial design determined by an orthogonal array,
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to the minimum number of profiles that allows estimation
of the attribute (main) effects. The resulting 16 profiles
were used to form all possible pairs of distinct profiles,
120, each pair representing an unlabelled choice question.
Eight different choice questions were randomly allocated
and presented to each household head in a community
survey of health-seeking behaviour for treating fever in
adults and children in the Zomba District of Malawi. The
methodological details of the survey have been reported
elsewhere [16]. Briefly, households were selected by two-
stage cluster sampling with stratification (by area; rural and
urban vs. peri-urban) from all the traditional authority
units in Zomba. Participants living in urban (all townships,
town planning areas and district centres), peri-urban
(settlements within 20 km of urban boundaries) and rural
areas (others) were face-to-face interviewed in the local
language, Chichewa, by trained fieldworkers. In each
choice question, the respondent had the option to state
one of the two profiles as their preferred treatment for
their own malaria or that they had no preference between
the two options or that they would refuse choosing any
of the two options. Additional information on the house-
hold head’s age, sex, education, occupation, experience of
using an anti-malarial drug, anti-malarial drug experi-
enced, sleeping under a bednet the previous night, and
household per capita monthly expenditure, was used to
analyse patterns of refusal to make a selection and het-
erogeneity in attribute effects.
This design corresponds to a ratio of 120 options in
different combination sets to 14 degrees of freedom,
which provides adequate power for estimating all main
effects [17]. In cases where the random allocation yielded a
choice question involving the same profile in both options,
the random draw was repeated until the question pre-
sented the respondent with a choice between two different
profiles. The final design had a block diagonal covariance
matrix and it was 57% D-efficient [18].
Cartoon aids (Additional file 1) were used to present
the experimental choice questions to respondents. The
format was pilot tested in a sample of participants (n = 16).
The use of cartoons was found to facilitate the cognitive
task demanded by the experiment, in particular the com-
munication of magnitudes of pruritus risk and treatment
duration. The pilot questionnaire took between 10–15 mi-
nutes to complete and no difficulties with understanding
questions or providing responses were reported by the
participants. In particular, the tools were found to yield
valid answers among illiterate respondents, the majority of
whom were found in rural areas.
Data collection forms were standardized and double
entered into SPSS databases. Only study numbers were
used as personal identifiers. Data records were treated
confidentially and only available to the staff directlyconcerned with this research. Ethical approval was ob-
tained from the University of Zomba in Malawi and the
Research Ethics Committee of the Liverpool School of
Tropical Medicine. No monetary compensation was given
to study participants.
Data analysis
Responses to choice questions were analysed according
to a model of random utility where, in a choice scenario
involving two options, an option, say ‘Option 1’, would
be selected according to the following principle:
U(Option 1) > U(Option 2)
where U, the utility of an option, is a function of its at-
tributes. Utility is represented as a latent linear function;
that is:
U Optionj
 
¼ αCj þ νFj þ γRj þ δPj þ ζDj
þ ηHj þ εj; ð1Þ
where C is the drug price, F is time to fever resolution,
R is pruritus (rash) risk, P is the duration of protection
from reinfection, D is the treatment duration, and H
indicates whether the drug is recommended by a health
professional; α, ν, γ, δ, ζ, η are the parameters (effects) to
be estimated and ε is the random part of the model. The
effect on the drug option’s utility of a $1 increase in its
price, α, is equal to the negative of the marginal utility of
income under the assumption of constant marginal util-
ity, and may thus serve as reference to value the other
effects. For example, the ratio ζ/α, gives the monetary
rate or price reduction an individual is willing to accept
as compensation for one extra day of drug therapy; i.e.
the marginal willingness to pay for one day less of treat-
ment (since both parameters are expected to be negative).
The selection of Option 1, say, is interpreted here as:
αC1 þ νF1 þ γR1 þ δP1 þ ζD1 þ ηH1 þ ε1 > αC2
þνF2 þ γR2 þ δP2 þ ζD2 þ ηH2 þ ε2
which may be expressed as:
β0X1 þ ε1 > β0X2 þ ε2
or equivalently:
αΔC þ νΔF þ γΔRþ δΔP þ ζΔDþ ηΔH > ε2−ε1
ð2Þ
where variables with the suffix 1 refer to the character-
istics of Option 1, while variables with suffix 2 refer to
the other option, and β’X is the shorthand expression of
the linear combination of attribute and coefficient prod-
ucts (β’ stands for the transposed vector of parameters
and X for the vector of attributes) and Δ denotes the
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ing value for option 2. Thus, an option with a lower cost
than the alternative and equal values for all other attri-
butes and distribution of error term, will have a higher
probability of being chosen as long as α is negative. The
probability will depend on the specific value of α and
the probability distribution of the random error terms
ε1 and ε2. The most common distributions imposed on
these terms include the logistic (logit) and normal (probit)
distribution, since they involve simple probability functions
(the probit is more complex in the case of more than two
options). In general, the choice between the two makes no
significant difference [19].
The (random effects) logit (i.e. mixed logit) form was
chosen since it combines the convenience of the logit
form with the simplicity of modelling the effect of unob-
served individual heterogeneity in the attribute effects
in answers to repeated choice questions by the same
individual as random normal coefficients. Thus, a random
error varying across individuals but remaining constant
within choices by the same individual was specified for
each attribute’s coefficient, assuming independence be-
tween errors of different coefficients. In addition hetero-
scedasticity across location of residence was allowed for
by two scale parameters: one associated with living in an
urban area and another for observations from peri-urban
areas.
The model was estimated using simulated maximum
likelihood, by modifying the likelihood and gradient
functions of the GAUSS (Mathematical and Statistical
System™) programme mixed logit estimation by max-
imum simulated likelihood by Kenneth Train [20], with
a modification to allow for heteroscedasticity using
different variance scale parameters for rural, urban and
peri-urban observations. The likelihood (L) of each
choice by an individual in the model was:
L ¼ y exp β’X1ð Þ
s
X2
i¼1exp β’Xið Þ
s
h iþ 1−yð Þ
 exp β’X2ð Þ
s
X2
i¼1exp β’Xið Þ
s
h i
ð3Þ
Where y is the choice indicator taking the value of 1 if
option 1 is selected and 0 otherwise; β’x1 and β’x2 are
the vectors of attributes and coefficients for the two op-
tions in Equation 2, and the βs are random normal param-
eters; the term s is a variance scale parameter ≡ mu + 1-u,
taking the value of 1 if the respondent lives in a rural
area (u=0) or m, if resident of an urban settlement (u=1).
The parameter m is simply the ratio of the variance of
responses from persons in rural areas to the variance
of responses from urban residents: a value of 1 impliesequal urban and rural variances whilst higher values sig-
nal higher rural variance. Two variance scale parameters
(relative to rural variance) were estimated, one for urban
and another for peri-urban residents. The effect of a
(marginal) change in the value of an attribute is a
(nonlinear) function of the initial covariate (attribute)
values, the βs and the value of m; this allows for the pos-
sibility of the same change having a different effect on
the probability of choice in the three types of population
settlement; the direction of effect is given by the sign of
the coefficient of the varying attribute. The product of
likelihood terms as Equation 3 for all choices across all
individuals is the likelihood function; the estimated
parameters are the value of the βs (and their standard
deviations) and the scale variance terms at which the
function achieves its maximum value. Weights were used
in estimation to reflect the survey design [16] and to
obtain representative attribute coefficient estimates for
the head of household population in the district.
The working hypothesis is thus that the separate
effects of a higher cost, greater risk of side effects (i.e.,
rash), longer time to fever resolution, and longer treat-
ment course duration are negative, so that higher values
for these attributes are considered to imply less attract-
ive drug options, whereas recommendation of the drug
in question by a health professional and a longer dur-
ation of prophylactic effect are expected to make an
anti-malarial drug treatment option more attractive to
users. Results are presented for the attribute coefficients
in the linear index (β in Equation 2) and, for attributes
other than health professional recommendation, as the
ratio of relative change in the probability of selection to
the proportional change in the respective attribute level
(elasticity); for the health professional recommendation
attribute, the odds ratio was used instead of the elasti-
city, since this was not defined.
Results
The stated preference questionnaire was presented to
the 508 household heads included in the community
survey. From these, 55 household heads (13%) had one
or more choice data missing from their records, resulting
in 164(4.04%) unanswered choice questions, with one par-
ticipant declining to answer the questionnaire. Responses
of all individuals were included in the analysis.
Table 1 shows descriptive statistics about the partici-
pants, including socio-economic characteristics, malaria
prevention behaviour, experience with anti-malarial treat-
ment and the proportion of questions where individuals
declined to select any of the two options presented.
The sex ratio was equal in urban and peri-urban areas,
whereas 63% of participants in rural areas were male.
The proportion of individuals with no education is con-
siderably higher in the rural group (25% vs. 6.2%, in
Table 1 Choice data and participant characteristics
Variables Rural Peri-Urban Urban
N of participants 364 80 64
N of scenarios 2911 640 512
N of scenarios where no drug profile
was chosen (%)
129 (4.4) 23 (3.6) 12 (2.3)
Sex (Male)% 63.2 51.6 51.2
No formal education% 25.0 6.2 4.7
No formal occupation% 8.2 8.7 9.4
Radio at home% 69.5 88.8 98.4
Per capita monthly expenditure -$1 19.47 57.51 286.73
Household poor -%2 87.0 91.6 41.2
‘Preferred anti-malarial’:
SP 43.9 57.5 45.3
Quinine 5.2 13.7 20.3
Halofantrine/Mefloquine 0 0 9.4
Chloroquine 1.4 2.5 6.2
Antipyretic/painkiller 4.9 5 1.6
Antibiotic 7.4 3.7 0
No preferred anti-malarial 36.8 17.5 15.6
One respondent (0.27%) residing in a rural area stated having a preferred anti-
malarial but did not provide name.
1Exchange rate $1= Malawian Kwacha108.8374; average for February 2004;
source: IMF (2004). Reflated to 2006 prices using CPI (All items – US Bureau of
Labor Statistics; http://www.bls.gov/cpi/data.htm accessed 31 July 2007). n=28
cases had missing information on monthly expenditure; rural areas n=340
(6.60% non-response rate), in urban n= 63 (1.57% non-response), and peri-urban
n= 77 (3.75% non-response).
2Defined as household expenditure per capita below poverty line. Poverty line
in 2006: for urban areas, MK113.39 (US$ 0.91); rural south MK32.90 (US$0.25).
The poverty line for urban areas was used to classify per capita expenditure in
Peri-urban areas. Source: [21] http://www.ifpri.org/themes/mp18/malawipms/
pmsprofile.pdf. Poverty lines reflated to 2006 using the Rural and Urban (all
items) Consumer Price Indices for Malawi (NSO in http://www.nsomalawi.mw/
component/content/article/21.html accessed 1 August 2007).
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to essential means of information (i.e. no radio at home;
31% vs. 11% and 2%). The experience of anti-malarial
drug consumption appears to be more varied in urban
areas than the rest, with the proportion in rural areas not
having a preferred anti-malarial being twice that in urban
and peri-urban areas. No-one in rural or peri-urban areas
chose halofantrine or mefloquine, drugs that were not part
of the official treatment policy, as their preferred treatment,
although this was the choice for 9.4% of urban respondents.
The reasons behind respondents declining to select
any of the two drug profiles, was explored using logit
regression analysis. Choosing none of the profiles was
more likely without a formal occupation, but not related
to any other of the respondent characteristics analysed:
sex, education, bed net use, per capita household ex-
penditure, and preferred anti-malarial (see Additional
file 2). With regard to drug characteristics, the attribute
levels of price and health professional recommendationwere positively and negatively related to the probability
of a scenario having no chosen profiles.
The (weighted) analysis of responses (rural n=2,782;
peri-urban n=617; urban n=500; these numbers reflect
the household population distribution in Zomba, and
the over-sampling of peri-urban respondents from strati-
fication, which is corrected with the weighted analysis) is
presented in Table 2. This includes scenarios where
indifference between the two options was stated (n=10
by 9 participants; 0.25% overall), in which case a random
allocation to one of the two options was made. By in-
creasing the random noise, this random allocation in ef-
fect reduces the magnitude of the estimated coefficients
relative to the alternative of excluding those scenarios
with indifferent options.
Two models were estimated (see Table 2), Model 1
estimated normally distributed coefficients for all six
attributes. An alternative model, Model 2, restricted the
coefficients for cost, fever duration and risk of pruritus
to the negative domain, in line with the logic that an in-
dividual would generally consider these as undesirable
or ‘bad’ attributes, so that the higher their value, the less
attractive the option would become. Model 2 can thus
be considered as a form of sensitivity analysis to check
the robustness of results obtained from Model 1. It is
operationalized by specifying the parameters to be esti-
mated in each case as the mean and standard deviation
of the natural logarithm of the coefficient; since this
restricts the original coefficients to be positive, the re-
spective attributes (i.e. independent variables) are con-
verted to negative values.
The direction of effect for all attributes was as ex-
pected. On the second column of Table 2, which shows
results for the linear index in Equation 2, cost has a
negative coefficient, implying that, in a given choice, the
probability of selection of a drug would decrease (in-
crease) as a result of an increase (decrease) in its price
while all other attributes remain unchanged. Treatment
duration has also a negative effect: drug therapies with
longer treatment durations tend to be disregarded in
favour of otherwise similar drugs; its coefficient magni-
tude (−0.29) relative to that for cost (−0.63) implies a
marginal willingness to pay (accept) for shorter (longer)
drug regimes equal to $0.46 per additional day without
(with) treatment. For example, users would have to be
compensated for suddenly having to use a treatment
course that lasts 3 instead of 1 day by a price reduction
of $0.92 if they were to remain as likely to use the new
treatment as they were the old one (notice that at the
lowest price experimented with, $0.46, that price reduc-
tion translates into a negative price so that users would
have to be paid in order to entice them to entirely sub-
stitute the new, ‘ACT’, for the old, ‘SP’, option). A higher
pruritus risk also discouraged selection of a drug treatment
Table 2 Discrete choice model estimates by model variant (Linear index - Equation 2)
Model 1: Normally distributed coefficients
(N=508 respondents, 3899 responses)
Model 2: Log-normally distributed coefficients
(N=508 respondents, 3899 responses)
Variable Estimate
Coefficient [SD]
Standard error
Coefficient [SD]
Estimate
Coefficient [SD]
Standard error
Coefficient [SD]
Cost($) −0.63 [0.52] 0.05*** [0.06]*** n/a n/a
Fever duration1 −0.11 [0.03] 0.01*** [0.03] n/a n/a
Risk of rash −1.27 [0.76] 0.09*** [0.10]*** n/a n/a
Savings($) (i.e. inverse of cost) n/a n/a −0.76 [1.59] 0.14*** [0.38]***
Days without fever (i.e. inverse of fever duration) n/a n/a 0.015 [0.02] 0.011 [0.02]
Probability of no side effect (i.e. inverse of
risk of rash)
n/a n/a 0.14 [0.90] 0.09 [0.13]***
Official treatment 3.06 [2.29] 0.24*** [0.22]*** 3.44 [2.42] 0.32*** [0.32]***
Prophylaxis duration 0.05 [0.04] 0.004*** [0.005]*** 0.06 [0.04] 0.005*** [0.006]***
Course duration −0.29 [0.06] 0.05*** [0.11] −0.32 [0.20] 0.06*** [0.13]
Relative variance: Urban vs. rural1 1.59 [0] 0.37 1.43 [0] 0.30
Relative variance: Peri-urban vs. rural1 0.91 [0] 0.19 0.85 [0] 0.19
−2 x(Mean simulated Log-likelihood ratio)2 47.4*** 10.40
Note: only coefficient estimates with asterisks alongside their standard errors had p<0.05.
*** p<0.001. n/a: not included in model.
1. Relevant test for relative variances is Ho: Variance urban/ Variance rural =1, and Variance peri-urban/ Variance rural=1, so p>0.05 (for urban vs. rural and peri-urban vs.
rural, separately, and, or jointly using the simulated log-likelihood ratio tests –results not presented but available from authors).
2. Quasi-likelihood ratio test of the null hypothesis that all attribute fixed coefficients being equal to 0 (Note that in the case of Model 2, where three coefficients
are log normally distributed –for cost, fever resolution, and risk of rash- this hypothesis is equivalent to their being jointly insignificantly different from 1, along
with the normally distributed coefficients being zero). The test statistics are distributed in both cases as χ(6 degrees of freedom).
Model was estimated using simulation with n=100 repetitions.
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in terms of prophylaxis duration, users would prefer, ac-
cording to our findings, the one with the longer period
of protection. Everything else equal, drugs with faster
symptom relief were preferred, as were those recom-
mended by a health professional.
In the effect of attributes other than speed of fever
resolution and treatment duration, data are consistent
with patient heterogeneity: a minority of individuals
would value them contrary to the ‘common sense’ view.
In the case of cost, a standard normal cumulative distri-
bution of respondents with mean −0.63 and standard
deviation 0.52 implies that 11.3% (z=1.21) of individuals
had the view that, everything else being equal, more
expensive drugs are more attractive. Similarly 4.7%
(z=1.67) of individuals would find treatments with a higher
risk of rash to be more attractive than less risky treatments.
The SD coefficient for fever duration is not statistically
different from zero at the 5% significance level, confirming
the widely held association of speed of fever resolution
with quality by anti-malarial drug users.
Results for Model 2 (fourth and fifth columns, Table 2)
seem to confirm those for Model 1. The respective inde-
pendent variables were adjusted to account for the fact
that log-normal random coefficients are by definition
positive, so that, for consistency with a priori expecta-
tions, these variables were entered in the estimationprocedure as savings (negative costs) or goods (negative
‘bad’, i.e. for rash, the probability of no side effect, whilst
for fever duration, the number of days without fever).
The interpretation of the coefficients themselves is also
different to that for Model 1 since a log normal distribu-
tion of mean zero is distributed around the value of 1; it
may be seen that those coefficients corresponding to the
probability of no side effects and days without fever,
whose counterparts in Model 1 had values of −1.27
and −0.11, are not significantly different from zero at
conventional levels and imply 95% CI of −1.38 to −0.96
and −1.03 to −0.99 under Model 2. Notice that the vari-
ance for days without fever does not appear significant at
the 5% level. Other results are consistent with the results
from Model 1.
Both models sought also to infer whether a difference
existed between rural and other areas in the variance of
the (logit model) error term. In Model 1, the estimated
ratio of variances was 1.59 for the urban versus rural
comparison, while that corresponding to peri-urban ver-
sus rural was 0.91. The test statistic for the relative vari-
ance coefficient of urban areas (Model 1: z= (1.59-1)/
0.37 = 1.6) has an associated p=0.12, consistent with the
variance ratio being 1 (equal variances) at the 5% level of
significance. The respective test statistic for the peri-
urban area (Model 1: z= (1–0.91)/0.19 = 0.48) has p=
0.63. Similar findings apply to Model 2. Therefore, the
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viduals from different areas were found not to be statisti-
cally significant.
The analysis also explored the effect of covariates on
stated choices and the robustness of random terms. The
random coefficients of drug price, pruritus risk, prophy-
laxis effect duration and recommendation by a health
professional were all robust to adding interaction terms
between age, sex, lack of education, and monthly house-
hold expenditure covariates and the attributes (see
Additional file 3). The effect of price was smaller in re-
spondents from households with higher monthly expend-
iture, while it was larger among respondents with no
education. After adjusting for these covariates, the inter-
action between the price attribute and an indicator for
urban residence had p>0.05. The price and peri-urban
interaction, however, was positive and had a p=0.032.
Other interactions had p>0.05 (see Additional file 3).
Table 3 presents the sensitivity or elasticities of drug
choice with respect to each attribute as a measure of
their relative importance. The elasticity is the propor-
tional change in probability of choosing an anti-malarial
profile due to varying the value of one attribute divided
by the proportional change in the value of the attribute
(figures are absolute values). The elasticities are calcu-
lated with reference to the probability of choice for an
official, one day treatment course, valued at $0.46, with
10 days of prophylactic effect and a 1 in 10 risk of rash
developing from its intake, and that takes 12 hours to
resolve the fever. The alternative drug profile is specified
to be different only with respect to cost, at $1.10, and
duration of treatment course, set at three days. At theseTable 3 Elasticities of choice probability relative to each
attribute*
Attribute Mean (SD) Median (Interquartile range)
Cost 0.08 (0.05) 0.06 (0.03 – 0.12)
Fever duration 0.76 (0.23) 0.88 (0.78 – 0.89)
Risk of rash 0.35 (0.29) 0.25 (0.08 – 0.62)
Duration of prophylaxis 0.01 (0.01) 0.02 (0.003 – 0.02)
Treatment course duration 0.08 (0.04) 0.09 (0.05 – 0.10)
*In absolute values. Based on results of estimated model 2, fixing variance to
be the same across residential groups (urban, rural and peri-urban) and with a
fixed coefficient for the treatment course duration and fever duration variables; the
fixed part of the random (log normal) coefficient of the risk of rash variable was
fixed at zero in view of estimation results (see columns 4 & 5 of Table 2).
Elasticities were calculated for an official treatment option with the following
specification: Cost MK50 ($0.46), Time to Fever resolution 12 hours, Risk of
Rash 1 in 10, Duration of Prophylactic effect 10 days, Treatment course
duration 1 day. The alternative differed from the option whose attributes were
varied in terms of Cost (MK120; $1.10) and Treatment Course Duration
(3 days); the price is based on results of price-tracking retail surveys of ACTs
subsidized by the Global Fund to Fight AIDS, TB and Malaria in Ghana, Kenya,
Nigeria and Tanzania [22]. At these values the initial probability of use (market
share) of the treatment option that is affected by the change of value in each
attribute described by the Table is 76.9%. The predictions were calculated
using n=50 repetitions.values, the duration of fever is the most influential attri-
bute (i.e. the one relative to which demand is most sen-
sitive or elastic) whereas the duration of the prophylactic
effect is the least important; a ten percent reduction in
the speed of symptom (fever) resolution (i.e. from 12 to
13.2 hours) would result in a decrease in the likelihood
that the affected drug therapy be chosen of 7.6% (i.e.
from 77% to 71%); at the other extreme, a 10% increase
in the duration of the prophylactic period (i.e. from 10
to 11 days) would only increase the likelihood of choice
by 0.1%. Cost is seen as secondary to drug safety (i.e. the
absence of rash), which in turn appears to be the second
most important attribute. The duration of regimen is as
influential as cost, and more so than duration of prophy-
lactic effect of the drug. Health professional recommen-
dation made drug selection more likely, by a median
odds ratio of 36.4 (IQR: 2.1 -141.3).
The proportion of patients invariably choosing the
option with the lower/higher attribute value or indicator
(recommended by a health professional, ‘yes’/’no’) among
those who happened to be allocated five or more scenar-
ios with different values across options for the attribute
in question was: cost, 17.2% (95% CI: 13 – 21); symptom
resolution 4.4% (2 – 7); risk of rash, 26.3% (20 – 32);
recommendation by health professional, 36.5% (30 – 43);
prophylactic effect 21.8% (16 – 27); regimen duration
5.2% (2–8). That is, 63.5%, and possibly up to 70%, of
individuals are willing to consider using drug treat-
ments other than those endorsed by the formal healthcare
system.
Discussion
The results of this representative survey of heads of
households randomly sampled from all households in
the district of Zomba, Malawi, suggest that, on average,
the five drug-related and the one healthcare policy tool
attributes investigated significantly affect individual
adults’ own treatment choices, and do so in the direction
predicted a priori. There is heterogeneity in user appre-
ciation of some attributes, i.e., cost, risk of side-effects
(rash), treatment recommendation by a professional, and
duration of prophylaxis. While for rash risk this implies
counter-intuitive behaviour in a small minority of indi-
viduals that may result from misspecification of the nor-
mal functional form for random coefficients, for other
parameters it may reflect genuine behavioural traits. For
example, it is estimated that almost 9% of individuals
would consider endorsement of an anti-malarial by a
health professional as a disincentive to use it. This result
is robust to accounting for household expenditure and
level of education of respondents in the analysis.
Perhaps more significant is that up to 70% of individ-
uals in Zomba may be prepared to consider using drugs
other than those recommended by health professionals.
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policy for drug treatment choice in sub-Saharan Africa,
suggesting that individuals in the community do not in
general rely on the prescriptions of the formal system of
those countries and that, to be effective, policy must be
supported by other measures such as economic incen-
tives from price subsidies [23]. This is in line with the
findings of McCombie [1], and the observed frequency
with which informal sources of health care are sought
after fever onset in malaria endemic areas [16].
As expected, respondents were least willing to trade a
higher rash risk for an improvement in other attribute:
an estimated 20-32% of them would not do so. The most
important attribute in drug selection was the speed with
which an anti-malarial resolves fever; cost was only the
third most important factor after pruritus risk and speed
of fever resolution. In fact, the number of days that the
course lasts for was found to be as important as cost.
The prophylactic effect that drugs with slow rates of
drug elimination may confer was of minimal influence
on decisions to use an anti-malarial. These effects did
not differ according to whether respondents lived in a
rural, peri-urban or urban area.
Obtaining realistic choice scenarios is a common chal-
lenge in experimental studies. The frequent use of infor-
mal sources of treatment in the population [16] makes
the experimental choice situation familiar and realistic
enough for participants to provide valid responses to it.
A further issue in experimental studies is the difficulty
in conveying information on small risks or small vari-
ation of risks. The use of cartoon aids to communicate
the notion of rash was intended to facilitate the response
elicitation task to respondents, many of which would be
illiterate, while avoiding practical and analytical prob-
lems associated with negative affective effects or fear in-
duced by a more realistic graphic depiction of risk [24].
A relatively large variation in risk, from 1 to 3 in 10
cases, was selected and clearly accounted for by the par-
ticipants’ responses. While responses from 4.7% of indi-
viduals appear to imply, paradoxically, that high risk
treatments are preferable to otherwise similar treatments
of low risk, this result was not mediated by lack of edu-
cation, which suggests that illiteracy was not a barrier to
respondents’ understanding the task and may reflect the
benefits of using cartoon aids. The experimental design
allowed for indifferent responses and these turned out to
represent a negligible proportion of the total. It may be
relevant to assess smaller risk levels and differences, and
using cartoon aids as in this study represents a promis-
ing approach to the task.
The results highlight the ongoing challenges to accept-
ance of artemisinin combination therapy (ACT), which
is more expensive and requires a longer treatment
course than SP, the former official first-line treatmentstill widely used in the region and still available in some
informal outlets. A price subsidy on its own is likely to
have limited effect: bringing the price down to the same
level as that of SP would result in a predicted likelihood
of choice for ACT of 63% given a scenario with SP as
the alternative. In order to compensate for the disadvan-
tage of using ACT in terms of course duration (3 vs.
1 day), co-formulating the drug with or ensuring co-
prescription of an antipyretic to shorten the time to per-
ceived symptom resolution by users may be an effective
option to increase use; indeed, there is scope to pay for
such compounded treatment through the implicit will-
ingness of respondents to trade off a lower price subsidy
for faster symptom control.
In terms of social welfare, a non-zero price coefficient
of demand for an essential commodity to public health,
such as anti-malarial drug therapy in sub-Saharan Africa,
suggests its susceptibility to monetary incentives inde-
pendent of need and, consequently, possible misuse (i.e.
‘moral hazard’ in consumption). The same (negative)
price and attribute coefficients were estimated to apply
to rural, urban, and possibly peri-urban areas, implying
that willingness to pay for anti-malarial drug attributes
was the same across them. While the size of the study
may have been insufficient to estimate differences across
locations precisely, given that the cost of living in urban
areas of southern Malawi is almost four times that in
rural ones, the same nominal estimate of willingness to
pay for an attribute in both areas implies a higher eco-
nomic value to rural residents. This may partly reflect
implicit assessments of differential ease of access to pro-
viders between urban and other areas, since physical ac-
cess was not explicitly controlled for in the experiment.
It seems remarkable that nominal willingness to pay is
the same across areas under the observed disparities be-
tween the urban, rural and peri-urban samples in terms
of socio-economic living conditions, education and
household income. Thus while the effectiveness of mon-
etary incentives, such as price subsidies for ACT, is
likely to be the same across the three subpopulations,
optimization of social welfare under limited resources
may require allocating a higher drug price subsidy to rural
than to urban areas.
Conclusions
In summary, this study found that use of cartoon aids to
convey magnitudes of risk and other clinical attributes
facilitates the implementation of discrete choice experi-
ments in populations with high levels of illiteracy. Head
of households in a malaria endemic area of sub-Saharan
Africa are willing to use antimalarial treatments that
while conveniently addressing their symptoms may not
be those endorsed by health professionals. The results
suggest that policies aiming to improve the treatment of
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provision of economic incentives to users of a new anti-
malarial as a limited part of effective policy implementa-
tion measures. Indeed, given the limited margin for price
reductions, a full price subsidy complemented by a con-
ditional cash or in-kind transfer policy may be required
to steer users away from ineffective treatments and into
new effective ones. The study highlights the importance
of addressing the disaffection with the healthcare sys-
tem in sub-Saharan Africa, which predisposes individ-
uals to consume suboptimal treatments for potentially
life threatening endemic conditions [1,25]. Further stud-
ies should seek to conduct discrete choice experiments
with adequate power to address the question of the mag-
nitude of differences in price and treatment attribute
sensitivity between anti-malarial drug users of rural and
urban areas in order to determine optimal subsidies.
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